Overview

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Status:
Not yet recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

A prospective, open-label, multi-center, single-arm study of Almonertinib combined With Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis.

Phase:

N/A

Details

Lead Sponsor:

Second Affiliated Hospital of Nanchang University

Collaborator:

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Treatments:

Bevacizumab